Mutant T7 RNA Polymerase Thermal Stability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Wild-type T7 RNA polymerase exhibits reduced activity and nucleic acid amplification efficiency at temperatures above 46°C, limiting the effectiveness of isothermal nucleic acid amplification methods like TRC, which requires complex temperature control and hampers primer design due to RNA's complex structure at lower temperatures.

Innovation Solution

A mutant T7 RNA polymerase with improved thermal stability and specific activity is developed by substituting specific amino acid residues, such as glutamine at position 786 with hydrophobic amino acids and lysine at position 179 with glutamate or cysteine, enhancing its performance at higher temperatures.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If wild-type T7 RNA polymerase is used for isothermal nucleic acid amplification, then the reaction can be carried out at constant temperature, but nucleic acid amplification efficiency decreases at temperatures of 46°C or higher due to reduced polymerase activity

Engineering Contradiction:
Improveisothermal reaction conditionVSAvoidnucleic acid amplification efficiency
Core Design Contradiction:
Ease of operationVSProductivity

Solution Approach 1:

The patent applies parameter changes by mutating specific amino acid residues in the T7 RNA polymerase sequence (positions 179, 685, and 786) to alter the enzyme's thermal stability and activity characteristics. This enables the polymerase to maintain high activity at elevated temperatures (46-50°C), resolving the contradiction between isothermal operation and amplification efficiency by changing the biochemical parameters of the catalyst itself

Inventive Principle:
Principle #35Parameter changes

2Reliability

If wild-type T7 RNA polymerase is used at low temperatures (40-45°C), then polymerase activity is maintained, but RNA assumes complex higher order structure making primer design difficult

Engineering Contradiction:
Improvepolymerase activityVSAvoidRNA structure complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

By changing the amino acid composition of T7 RNA polymerase through site-directed mutagenesis, the patent shifts the optimal temperature range for polymerase activity from 40-45°C to 46-50°C. This parameter change in the enzyme's thermal characteristics allows RNA to remain in a simpler, more accessible conformation at the new optimal temperature, resolving the contradiction between maintaining polymerase activity and reducing RNA structural complexity

Inventive Principle:
Principle #35Parameter changes

3Stability of the object's composition

If T7 RNA polymerase activity is enhanced at high temperatures through mutation, then thermal stability improves, but specific activity may be affected

Engineering Contradiction:
Improvethermal stabilityVSAvoidspecific activity
Core Design Contradiction:
Stability of the object's compositionVSReliability

Solution Approach 1:

The patent carefully selects specific amino acid substitutions at positions 179, 685, and 786 that independently contribute to thermal stability while preserving or enhancing catalytic activity. The cumulative effect of these targeted parameter changes in the protein sequence achieves both improved thermal stability and maintained or improved specific activity at elevated temperatures

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The mutant T7 RNA polymerase can be viewed as a composite structure combining wild-type sequence elements with three specific mutant residues. This composite approach allows the enzyme to inherit the catalytic mechanism of the wild type while incorporating stabilizing mutations, achieving both thermal stability and high specific activity simultaneously

Inventive Principle:
Principle #40Composite materials

Data Source

PatentEP2316934B1RNA polymerase mutant with improved functions
Publication Date: 2015.05.13 TOSOH CORP
  • EP2316934B1 patent drawingFigure 1~2
  • EP2316934B1 patent drawingFigure 3~4
  • EP2316934B1 patent drawingFigure 5

AI summary

Disclosed is a T7 RNA polymerase mutant having improved thermal stability and/or specific activity in comparison with wild-type T7-like bacteriophage RNA polymerase, wherein at least one amino acid residue corresponding to at least one of the amino acid residues selected from the group at least consisting of glutamine at position 768, lysine at position 179 and valine at position 685 of the amino acid sequence that composes wild-type T7 RNA polymerase shown in SEQ ID NO: 6, is substituted with another amino acid.